Last reviewed · How we verify

Marketed Nicotine Lozenge

McNeil AB · Phase 1 active Small molecule

Marketed Nicotine Lozenge is a Small molecule drug developed by McNeil AB. It is currently in Phase 1 development. Also known as: NiQuitin™ lozenge.

At a glance

Generic nameMarketed Nicotine Lozenge
Also known asNiQuitin™ lozenge
SponsorMcNeil AB
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Marketed Nicotine Lozenge

What is Marketed Nicotine Lozenge?

Marketed Nicotine Lozenge is a Small molecule drug developed by McNeil AB.

Who makes Marketed Nicotine Lozenge?

Marketed Nicotine Lozenge is developed by McNeil AB (see full McNeil AB pipeline at /company/mcneil-ab).

Is Marketed Nicotine Lozenge also known as anything else?

Marketed Nicotine Lozenge is also known as NiQuitin™ lozenge.

What development phase is Marketed Nicotine Lozenge in?

Marketed Nicotine Lozenge is in Phase 1.

Related